Thinly traded nano cap Kitov Pharma (NASDAQ:KTOV) is up 26% premarket on increased volume in reaction to its announcement that
it has received a Notice of Intention to Grant from the European Patent
Office regarding a patent covering the use of NT-219, in combination
with EGFR antibodies and inhibitors, to treat cancer.
https://seekingalpha.com/news/3534329-kitov-pharma-nabs-european-patent-for-ntminus-219-shares-up-26-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.